One down, one to go: Arcutis' repurposed AstraZeneca drug clears first PhIII eczema trial

Arcutis Biotherapeutics is on a roll. Months after launching its topical formulation of an old AstraZeneca drug in plaque psoriasis, the company is touting positive Phase III data in atopic dermatitis.